Kura Oncology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
16.2%projected annual EPS growth
Analyst Coverage
12analysts covering
FY Revenue (est.)
$100Mnext fiscal year
FY EPS (est.)
-$3.23next fiscal year
Monitoring Framework
Key Performance Indicators
KOMZIFTI Net Product Revenue Quarterly5.8MTarget: Continued commercial ramp and expansion of market share in relapsed/refractory NPM1-mutant AML
Collaboration Revenue Annually12.5MTarget: 45000000 to 55000000
Cash, Cash Equivalents and Short-Term Investments Quarterly580.8MTarget: Sufficient to fund ziftomenib AML program through first pivotal Phase 3 KOMET-017 frontline trial results in 2028
Watch Items
- Ziftomenib clinical data readouts across combination regimens and treatment settingsTrigger: Efficacy and safety data from frontline and combination trials in 2026Action: Evaluate clinical profile to support ziftomenib as a broadly combinable backbone therapy in AML
- Darlifarnib (KO-2806) platform trial progressTrigger: Initiation of Phase 1a combination with daraxonrasib in KRAS-mutant pancreatic cancer in early 2027Action: Monitor safety, tolerability, and early efficacy signals of the combination platform
Research as of 19 Jun 2026